These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 38016838)

  • 1. Down syndrome and leukemia: An insight into the disease biology and current treatment options.
    Barwe SP; Kolb EA; Gopalakrishnapillai A
    Blood Rev; 2024 Mar; 64():101154. PubMed ID: 38016838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia.
    Ge Y; Dombkowski AA; LaFiura KM; Tatman D; Yedidi RS; Stout ML; Buck SA; Massey G; Becton DL; Weinstein HJ; Ravindranath Y; Matherly LH; Taub JW
    Blood; 2006 Feb; 107(4):1570-81. PubMed ID: 16249385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
    Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
    Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly sensitive detection of GATA1 mutations in patients with myeloid leukemia associated with Down syndrome by combining Sanger and targeted next generation sequencing.
    Terui K; Toki T; Taga T; Iwamoto S; Miyamura T; Hasegawa D; Moritake H; Hama A; Nakashima K; Kanezaki R; Kudo K; Saito AM; Horibe K; Adachi S; Tomizawa D; Ito E
    Genes Chromosomes Cancer; 2020 Mar; 59(3):160-167. PubMed ID: 31606922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome.
    Cabelof DC; Patel HV; Chen Q; van Remmen H; Matherly LH; Ge Y; Taub JW
    Blood; 2009 Sep; 114(13):2753-63. PubMed ID: 19633202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
    Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology.
    Xavier AC; Ge Y; Taub JW
    J Mol Diagn; 2009 Sep; 11(5):371-80. PubMed ID: 19710397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissecting stepwise mutational impairment of megakaryopoiesis in a model of Down syndrome-associated leukemia.
    Evans EJ; DeGregori J
    J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35838049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A unique role of GATA1s in Down syndrome acute megakaryocytic leukemia biology and therapy.
    Xavier AC; Edwards H; Dombkowski AA; Balci TB; Berman JN; Dellaire G; Xie C; Buck SA; Matherly LH; Ge Y; Taub JW
    PLoS One; 2011; 6(11):e27486. PubMed ID: 22110660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute Megakaryocytic Leukemia.
    McNulty M; Crispino JD
    Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31548219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
    Malinge S; Bliss-Moreau M; Kirsammer G; Diebold L; Chlon T; Gurbuxani S; Crispino JD
    J Clin Invest; 2012 Mar; 122(3):948-62. PubMed ID: 22354171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.
    Sit YT; Takasaki K; An HH; Xiao Y; Hurtz C; Gearhart PA; Zhang Z; Gadue P; French DL; Chou ST
    JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid leukemia in Down syndrome.
    Khan I; Malinge S; Crispino J
    Crit Rev Oncog; 2011; 16(1-2):25-36. PubMed ID: 22150305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
    Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
    PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling.
    Bourquin JP; Subramanian A; Langebrake C; Reinhardt D; Bernard O; Ballerini P; Baruchel A; Cavé H; Dastugue N; Hasle H; Kaspers GL; Lessard M; Michaux L; Vyas P; van Wering E; Zwaan CM; Golub TR; Orkin SH
    Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3339-44. PubMed ID: 16492768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline GATA1s-generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype.
    Hasle H; Kline RM; Kjeldsen E; Nik-Abdul-Rashid NF; Bhojwani D; Verboon JM; DiTroia SP; Chao KR; Raaschou-Jensen K; Palle J; Zwaan CM; Nyvold CG; Sankaran VG; Cantor AB
    Blood; 2022 May; 139(21):3159-3165. PubMed ID: 34758059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.